Pilot of Rapid Assessment on ‘Zostavax for the prevention herpes zoster’ available

News

September 23, 2013

The first pilot of rapid assessment of WP5 JA2 Strand A on ‘Zostavax for the prevention herpes zoster’ is now available.

We are pleased to announce the publication of the first pilot rapid assessment of WP5 JA2 Strand A. This pilot rapid assessment evaluates the herpes zoster vaccine ‘Zostavax’ and its prevention of herpes zoster and post herpetic neuralgia.’

Please find the report including appendices here.

In case of any questions, please contact Lidia Becla (lbecla@cvz.nl).

OUR NETWORK

CAREERS

HELP

eunethta@zinl.nl

CONTACT US

This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.